Clinical Trial

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

Study acronym: DURGA-4
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethasone\], DPd \[daratumumab, pomalidomide, and dexamethasone\], PVd \[pomalidomide, bortezomib and dexamethasone\], or Kd \[carfilzomib and dexamethasone\]) in participants with RRMM.
Protocol Amendment History 5 changes
notable Trial sites expanded: 138 -> 142 locations 2026-08-07
notable Trial sites expanded: 116 -> 138 locations 2026-07-01
notable Trial sites expanded: 111 -> 116 locations 2026-06-12
notable Trial sites expanded: 108 -> 111 locations 2026-05-01
notable Primary completion moved earlier: 2028-08-30 -> 2028-06-14 2026-05-01
Trial Details
NCT Number NCT07391657
Lead Sponsor AstraZeneca
Conditions Relapsed Refractory Multiple Myeloma
Enrollment 508 participants
Start Date 2026-02-23
Primary Completion 2028-06-14 (estimated)
Study Completion 2030-07-29 (estimated)
Updated on ClinicalTrials.gov 2026-08-06